AVAV AeroVironment

Research status: Primary-source refreshed through Q1 FY2027 results, the 10-Q and September 2026 directed-energy awards. Valuation reference: $159.95 close on 18 Sep 2026.

The Q1 evidence improves the operating case but does not yet make AVAV an automatic buy. Q1 revenue was $480.5M, +6% YoY, bookings were roughly $0.7B, book-to-bill 1.4x, and funded backlog reached a record $1.5B, +37% YoY and up from $1.2B at fiscal year-end. Gross margin improved to 26% from 21% as purchase-accounting charges declined. GAAP operating loss narrowed to $10.9M and net loss to $5.1M, while adjusted EBITDA was $53.4M and adjusted diluted EPS $0.59. Management maintained FY2027 guidance of $2.125–2.225B revenue, $305–325M adjusted EBITDA and $3.02–3.34 adjusted EPS, with GAAP net income now guided to $10–27M.

Most importantly for the BlueHalo thesis, September supplied concrete funded directed-energy evidence: AV announced a $464.8M U.S. Army E-HEL production contract for LOCUST and a >$50M first international LOCUST order. This is stronger evidence that the acquired directed-energy portfolio is moving from strategic narrative toward funded production. The remaining question is per-share/cash economics: adjusted EBITDA declined modestly YoY despite higher revenue, GAAP profitability is only near breakeven, and manufacturing/capacity investment remains substantial.

AVAV remains investigate, but the thesis has strengthened. The next comparison should be against KTOS/MRCY/TDY on funded growth, margin quality, cash conversion and valuation rather than treating AVAV as a generic defence-growth name.

Investment case

AeroVironment combines combat-proven autonomous/loitering systems with BlueHalo's counter-UAS, space, cyber and directed-energy portfolio. Q1 FY2027 and the September LOCUST awards materially improve the evidence that this breadth can convert into funded production rather than remain acquisition narrative.

> The PowerFund thesis is that AVAV can become a scaled mid-tier defence technology platform if funded autonomy and counter-UAS/directed-energy programs compound while BlueHalo integration produces improving GAAP and cash economics. Q1 strengthened the demand/backlog side of that thesis; cash conversion and per-share profitability remain the evidence gates.

Q1 FY2027 baseline

• Revenue: $480.5M, +6% YoY.
• Autonomous Systems revenue: $346.0M; Space, Cyber & Directed Energy: $134.5M.
• Bookings: ~$0.7B; book-to-bill 1.4x.
• Funded backlog: $1.5B, +37% YoY and +$0.3B sequentially.
• Gross margin: 26%, versus 21% YoY, helped by lower purchase-accounting charges.
• GAAP operating loss: $10.9M; GAAP net loss $5.1M.
• Adjusted EBITDA: $53.4M, versus $56.6M YoY.
• Adjusted diluted EPS: $0.59, versus $0.32 YoY.
• FY2027 guidance maintained: revenue $2.125–2.225B, adjusted EBITDA $305–325M, adjusted EPS $3.02–3.34, GAAP net income $10–27M.

Funded programme evidence

• E-HEL / LOCUST: $464.8M U.S. Army production contract announced 2 Sep 2026; company describes it as the first U.S. directed-energy production contract.
• International LOCUST: >$50M first international commercial order announced 8 Sep 2026.
• Other disclosed awards include Switchblade 600, P550/LRR and additional space/counter-UAS programs, supporting a broader funded programme base.

KPI ladder

Prior 24/60-month valuation scenarios remain provisional pending a fresh defence peer comparison and cash-conversion update.

• Conversion of the $464.8M E-HEL award and >$50M international LOCUST order into revenue, margin and cash flow.
• Additional Switchblade/P550/counter-UAS funded production awards.
• Funded backlog remaining above ~$1.2–1.5B with book-to-bill >1x.
• BlueHalo-originated programs demonstrating cross-sell and recurring production economics.
• GAAP profitability and cash conversion catching up with adjusted EBITDA.
• Manufacturing expansion supporting larger production lots without margin erosion.
• Allied defence spending and autonomous/counter-UAS procurement acceleration.

• Per-share/cash quality remains unproven: Q1 adjusted EBITDA was $53.4M versus $56.6M YoY despite revenue growth, and GAAP earnings remained slightly negative.
• Acquisition/integration: BlueHalo strategic proof is improving, but purchase-accounting charges and integration complexity remain material.
• Backlog conversion: $1.5B funded backlog is positive only if programmes convert on schedule and at acceptable margins.
• Capacity/capex: manufacturing expansion must earn attractive returns rather than simply support headline growth.
• Procurement/funding: U.S./allied program timing can be lumpy and exposed to appropriations/continuing resolutions.
• Programme concentration/execution: large awards such as E-HEL create production and delivery obligations as well as upside.
• Competition: primes and newer defence-tech firms remain aggressive across autonomy and counter-UAS.
• Valuation: stronger evidence can still be offset by paying too much for expected programme growth.

Warning — freeze additions

• Funded backlog falls below ~$1.2B or rolling book-to-bill <1x for two quarters.
• Adjusted EBITDA margin fails to improve toward the FY2027 framework despite backlog growth.
• GAAP/adjusted EPS gap stops narrowing.
• Major new production awards require disproportionate capex/working capital without cash conversion.

Reduce / pass

• Funded production awards slip materially or convert at structurally weak margins.
• Organic/funded growth falls to mid-single digits while defence procurement remains strong.
• Another material goodwill/intangible impairment occurs.
• Cash conversion remains weak despite positive adjusted EBITDA and growing backlog.

Invalidate

> Invalidate if AVAV's strategic breadth and funded programme wins fail to translate into durable cash-generative per-share growth.

Additional hard invalidators: major control/accounting failure, loss/cancellation of a key autonomy or directed-energy production programme, or sustained negative cash conversion despite positive adjusted EBITDA.

AVAV now sits between traditional primes and newer defence-tech firms.

• Anduril/Shield AI: strong autonomy/software narrative and private-market capital.
• Traditional primes: deeper procurement relationships and scale.
• Teledyne FLIR: strong sensing/unmanned portfolio.
• AVAV: combat-proven loitering munitions plus a broader BlueHalo portfolio.

The potential moat is not any single drone. It is a portfolio of fielded autonomous/kinetic/counter-UAS capabilities that can share customers, integration and manufacturing. The proof must be funded cross-platform awards and improving cash returns.

1. Reconcile Q2/FY2027 revenue and bookings by Autonomous Systems versus Space/Cyber/Directed Energy; distinguish organic growth from acquired contribution where disclosure permits.
2. Build a funded-program map for E-HEL/LOCUST, Switchblade, P550/LRR and major counter-UAS/space awards: funded value, production start, expected duration, margin/capex requirements and follow-on potential.
3. Track conversion of the $464.8M E-HEL and >$50M international LOCUST awards into backlog, revenue and cash; treat these as the first concrete test of BlueHalo directed-energy value creation.
4. Reconcile adjusted EBITDA/EPS to GAAP and operating/free cash flow; quantify working-capital use as production scales.
5. Track manufacturing/facility capex by programme and test whether funded backlog and margins justify the investment.
6. Compare AVAV with KTOS, MRCY and TDY on funded growth, margin quality, cash conversion, leverage/capex and valuation before allocating new Defence capital.

Next full review: after Q2 FY2027 results, or earlier on a material funded programme change/cancellation or major defence-funding event.